Ads
related to: lung cancer targeted therapy review- Treatment Modifications
View Treatment Modifications
To Manage Adverse Reactions.
- Prep & Admin
Preparation & Administration For
Lung Cancer Immunotherapy.
- See Dosing Schedules
Find Dosing Information For This
1L NSCLC Dual I-O Option Today.
- View All Indications
Explore All Indications And See
The Range Of Treatment Options.
- Explore Patient Programs
Visit Access And Support Site
& View Resources For Your Patients.
- Review Clinical Data
Explore Efficacy & Safety Info
For This Treatment Option.
- Treatment Modifications
Search results
Results From The WOW.Com Content Network
Targeted therapy of lung cancer refers to using agents specifically designed to selectively target molecular pathways responsible for, or that substantially drive, the malignant phenotype of lung cancer cells, and as a consequence of this (relative) selectivity, cause fewer toxic effects on normal cells.
There are targeted therapies for lung cancer, colorectal cancer, head and neck cancer, breast cancer, multiple myeloma, lymphoma, prostate cancer, melanoma and other cancers. [ 1 ] [ 4 ] [ 5 ] Biomarkers are usually required to aid the selection of patients who will likely respond to a given targeted therapy.
In 2019, the FDA granted accelerated approval to pembrolizumab for people with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. [49] Non-small cell lung cancer (NSCLC) cells expressing programmed death-ligand 1 (PD-L1) could interact with ...
Cancer treatments are a wide range of treatments available for the many different types of cancer, with each cancer type needing its own specific treatment. [1] Treatments can include surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy including small-molecule drugs or monoclonal antibodies, [2] and PARP inhibitors such as olaparib. [3]
NVL-655 is a fourth generation targeted therapy (currently in clinical trials), developed by Nuvalent. [14] [15] Although treatment with immune checkpoint inhibitors has proved effective with some types of non-small cell lung cancer, it seems to be generally ineffective with ALK positive non-small cell lung cancer. [16]
Sotorasib is the first approved targeted therapy for patients with tumors with any KRAS mutation, which accounts for approximately 25% of mutations in non-small cell lung cancers. [5] KRAS G12C mutations occur in about 13% of patients with non-small cell lung cancers. [5]
Ads
related to: lung cancer targeted therapy review